Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Early Therapeutic Interventions for Diabetic Retinopathy Don’t Help Patients 
Clinical Breakthroughs

Early Therapeutic Interventions for Diabetic Retinopathy Don’t Help Patients 

By Melissa RohmanFeb 27, 2023
Share
Facebook Twitter Email
Lee Jampol, MD, the Louis Feinberg, MD, Professor of Ophthalmology, was a co-author of the study published in JAMA. 

Patients with moderate to severe nonproliferative diabetic retinopathy — which occurs when diabetes damages blood vessels in the retina — who received early therapeutic intervention with anti-VEGF medication injections saw no improvement in their visual acuity compared to patients given a placebo, according to a recent clinical trial published in JAMA. 

“This means that a large number of patients do not have to be treated prophylactically and many of those will not have to be treated at all. Watchful waiting was just as good as immediate initiation of therapy. This saves money and patient’s and physician’s time and effort,” said Lee Jampol, MD, the Louis Feinberg, MD, Professor of Ophthalmology and a co-author of the study.  

Diabetic retinopathy is the leading cause of blindness in adults, but the disease can be treated by controlling a patient’s blood sugar level, blood pressure and cholesterol levels through medications and lifestyle modifications. Laser eye treatments, such as a focal laser and panretinal photocoagulation, can also be effective, as well as directly injecting the eye with anti-VEGF medications, which decrease blood vessels from leaking and bleeding, which can cause severe damage.  

For patients with severe cases of diabetic retinopathy, effective treatments include panretinal photocoagulation or anti-VEGF injections. However, it had remained understudied whether patients with pre-proliferative diabetic retinopathy – those who were only beginning to show marked damage to the retina – would actually benefit from earlier anti-VEGF injections.  

In the randomized clinical trial, more than 300 patients from clinical sites across the U.S. and Canada who were diagnosed with pre-proliferative diabetic retinopathy received either a placebo (until severe changes occurred and are then treated) or anti-VEGF injections (aflibercept) every four months for two years.  

By the end of the study period, patients in both groups demonstrated similar long-term outcomes, with the same overall visual acuity. The findings suggest that earlier therapeutic intervention for these patients is unnecessary and provides no added benefit.  

“We believe that a reasonable approach in most patients is not to initiate therapy for this earlier stage, pre-proliferative retinopathy, instead waiting for the development of diabetic macular edema or proliferative diabetic retinopathy and then initiating treatment,” Jampol said. “The interventions of laser and anti-VEGF therapy are costly, time consuming and do not always work. We are therefore looking for better preventative therapeutic options.”  

This work was supported through a cooperative agreement from the National Eye Institute and the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institutes of Health, and the U.S. Department of Health and Human Services (EY14231).  

Ophthalmology Research
Share. Facebook Twitter Email

Related Posts

Hormone Therapy Plus Current Treatments Improves Survival in Prostate Cancer

Mar 22, 2023

How ChatGPT Has, and Will Continue to, Transform Scientific Research

Mar 21, 2023

New Directions for HIV Treatment

Mar 21, 2023

Comments are closed.

Latest News

Hormone Therapy Plus Current Treatments Improves Survival in Prostate Cancer

Mar 22, 2023

How ChatGPT Has, and Will Continue to, Transform Scientific Research

Mar 21, 2023

New Directions for HIV Treatment

Mar 21, 2023

Humans are Not Just Big Mice: Identifying Science’s Muscle-Scaling Problem

Mar 20, 2023

AOA Honors New Members

Mar 20, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230315_NM036
20230315_NM046
20230315_NM134
20230315_NM205
20230315_NM206
20230315_NM132
20230315_NM130
20230315_NM082
20230315_NM063
20230315_NM058
20230315_NM030
20230315_NM038

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.